• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
  • News
  • Lifestyle
  • Wellness
  • Cuisine
  • Product Reviews
  • Subscribe
Cannabis News and Culture Magazine

Cannabis News and Culture Magazine

Cannabis News and Culture Magazine

Emerald Media News Subscription
  • Print Magazines
  • 100+ Minority-Owned Companies to Support
  • No Pipe, No Problem
  • Blunt vs. Joint
  • The Cost of Cannabis in Each State
  • Calculating Your Edibles Dosage
  • Flintts Mouthwatering Mints

Are we one Step Closer to Getting the COVID-19 Vaccine?

November 25, 2020 by Laura Arman Leave a Comment

covid-19 vaccine

Since the World Health Organization (WHO) declared the novel coronavirus a pandemic on March 11th, 2020, drug makers have raced against the clock to curb the amount of  casualties from the virus. 

As of November 25th, the death toll from COVID-19 has reached 1,420,634 worldwide. The majority of the casualties come from the U.S. at 266,584, followed by Brazil at 170,199, and India at 135,165.

With all the pressure to produce a cure, big Pharma has begun mass testings for COVID-19 vaccines before they’re available to the public. 

Big Pharma Competes for a Cure

Moderna, a biotech company based in Massachusetts, has conducted a vaccine trail. The trial involved 30,000 people, according to a BBC report on the study. Half of the trial’s participants received two doses of the vaccine about four weeks apart. 

Overall, BBC reported, Moderna’s vaccine — which is not yet publicly available — shows 94.5% protection. 

Officials expect that vulnerable populations — including older Americans — will get the vaccine first. Approximately 20 million doses will be available in the U.S. in the coming weeks. 

covid-19 vaccine
Photo by Dimitri Houtteman

The British government, however, hopes to ensure access to Moderna’s vaccine by spring of 2021, according to Sky News. 

Sky News also reported that the vaccine lasts up to 30 days in household fridges, or at a room temperature for up to 12 hours. 

Other exciting news came from New York-based pharmaceutical company, Pfizer. 

Pfizer announced that its vaccine — BNT162b2 — is shown to be “95% effective against COVID-19.” 

Pzifer said it will produce 50 million doses in 2020, and another 1.3 billion by the end of 2021. Soon, the company will share its data with the Food and Drug Administration (FDA) and other regulatory agencies around the globe. 

Also, in collaboration with AstraZeneca plc, the University of Oxford, U.K., announced Phase III trials for its vaccine, ChAdOx1 nCoV-2019. The university staid the vaccine is “effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.”

They further announced that the vaccine is, on average, 70% effective.

The Vaccine’s Potential Side Effects

Although there’s hope, Dr. Sandra Fryhofer of the American Medical Association told CNBC that COVID-19 vaccines won’t be “a walk in the park.” 

Moderna and Pfizer both acknowledge that their vaccine could have side effects similar to mild symptoms associated with the virus, such as muscle pain, chills and headaches, CNBC reported.  

Participants of the Moderna and Pfizer vaccine trials told CNBC in September that they experienced high fevers, body aches, bad headaches, day-long exhaustion and other symptoms after receiving the shots. 

CNBC reported of a woman in her 50s who took part in the Moderna study. The woman said that although she didn’t experience a fever, she experienced a bad migraine for a day. But she said she woke up the next day feeling better.

Access for Developing Countries

Despite official approval, some countries are purchasing the vaccine in advance.

For instance, the BBC reported that Indonesia is partnering with Chinese vaccine developers, while Brazil is partnering with the University of Oxford and AstraZeneca.

Andrea Taylor, a Duke University analysis, told the publication, “we’re heading into a scenario where the rich countries will have vaccines and the poorer countries are unlikely to have access.”

covid-19 vaccine
Photo by Robert Bye

Rachel Silverman, a policy analyst at the Center for Global Development, explained to the BBC that there is little likelihood that the vaccines will get through low and middle income countries. She said that the most promising vaccines “are largely covered by advanced purchase agreements, mostly from wealthy countries.”

Also, due to remote conditions and limited electricity, poorer countries might have trouble meeting the cold storage requirements necessary for the vaccine. 

With this in mind, some world leaders, like Germany’s Chancellor, Angela Merkel, have urged leaders to promise fair distribution of the vaccines.  

According to NPR, during a G20 Global Summit on November 22nd, Markel emphasized that the progress of creating a distribution system for developing nations has been slow. 

“… I am somewhat worried that nothing has been done on that yet,” she said.

For now, Pfizer has applied for an emergency use authorization from the FDA and is expected to be reviewed in an advisory meeting in early December for potential authorization in the U.S. Within a month, some Americans could get their first dose of the vaccine. 

Written by: Laura Arman

High Pressure: FDA To Speed Up CBD Regulations

Filed Under: Culture Tagged With: AstraZeneca, coronavirus, COVID-19, Pfizer Moderna, University of Oxford, Vaccine

Reader Interactions

Leave a Reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

  • Facebook
  • Instagram
  • LinkedIn
  • Twitter
  • YouTube

Advertise Here

Categories

Sustainability

seaweed naturals

SeaWeed Naturals Combines the Power of Seaweed with Cannabis to Further Ocean Restoration

April 3, 2022 By Maggie Horton

fungi climate change

Research Finds Fungi Help Ease Climate Change and Benefit the Environment

March 30, 2022 By Julia Meyer

climate crisis and the pandemic

“We Can Act:” What Bending the COVID-19 Curve Teaches Us About the Climate Crisis

April 21, 2020 By Melissa Hutsell

Footer

  • Subscribe
  • About
  • Contact
  • Privacy
  • Press

Recent

  • How Much Dispensaries Make
  • Spain’s Largest Cannabis B2B Conference
  • Solful Becomes 1st Cannabis Dispensary to Join 1% for the Planet
  • Starting A Dispensary
  • Unlicensed Dispensary Donations

Search

Copyright © 2023 · The Emerald™ · News & Lifestyle Magazine

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

Cannabis News and Culture Magazine
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.